GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Illumina Inc.
Illumina is the undisputed leader in gene sequencing. Its stock price is a story of revolution in genetics and personalized medicine. The chart reflects the technology's enormous potential, but also its intense competition and dependence on scientific funding.
Share prices of companies in the market segment - Medanalysis
Illumina is the dominant leader in gene sequencing. We classify it as part of the Medanalysis sector. The chart below shows the overall dynamics of this revolutionary segment, where the company's value is determined by the pace of genomics' adoption in medicine and science.
Broad Market Index - GURU.Markets
Illumina is a global leader in DNA sequencing and genomic analysis technologies, whose equipment is used in scientific research and medicine. As a key biotech company, it is included in the GURU.Markets index. The chart below reflects the overall market performance. Compare its stock to the overall trend in the life sciences sector.
Change in the price of a company, segment, and market as a whole per day
ILMN - Daily change in the company's share price Illumina Inc.
For Illumina, a leader in gene sequencing, daily price changes are a measure of its response to scientific breakthroughs and research budgets. The graph of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
Illumina, Inc. is the leader in the DNA sequencing market. This chart illustrates the high volatility of the life sciences sector. A comparison with ILMN, whose sales depend on R&D budgets and the implementation of genetic technologies, helps us evaluate it as a barometer of medical innovation.
Daily change in the price of a broad market stock, index - GURU.Markets
Illumina is the undisputed leader in DNA sequencing technology. Its equipment forms the foundation for genomic research worldwide. The chart below shows overall market volatility, which can be used to assess how the market is responding to breakthrough biotech technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Illumina Inc.
Illumina, the dominant player in the genome sequencing market, has been through a challenging period of restructuring and competitive pressure over the past year. Its year-over-year share price performance, shown in the chart, reflects the market's assessment of these challenges and its long-term prospects.
Annual dynamics of market capitalization of the market segment - Medanalysis
Illumina, Inc. is the undisputed leader in the DNA sequencing market. Its technology is the foundation for genetic research and personalized medicine. This chart illustrates how its dominant position and long-term growth potential compare with current challenges such as competition and demand cyclicality.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Illumina is the dominant player in the DNA sequencing market. Its technology is the foundation for genetic research worldwide. The company's stock price in recent years has reflected increased competition and slowing growth, but its long-term potential in medicine remains enormous.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Illumina Inc.
The value of Illumina, a leader in DNA sequencing, depends on funding cycles in the biotech and science industries. The monthly fluctuations on the chart reflect the demand for its equipment and consumables from research labs and pharmaceutical companies, which depends on their R&D budgets.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Illumina, Inc. is the undisputed leader in the DNA sequencing market, providing the instruments and reagents that power the genomic revolution. The sector's dynamics, shown in the graph, reflect the pace of scientific discovery. This allows us to assess how Illumina's technology is being used in oncology, reproductive health, and research, changing the face of modern medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Illumina is a global leader in DNA sequencing. Demand for its equipment depends on research budgets, which are planned over the long term and less susceptible to short-term economic cycles. The chart below illustrates general market fluctuations, which can impact Illumina's unique performance.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Illumina Inc.
Shares of Illumina, a leader in genome sequencing, react weekly to news from the worlds of science and medicine. Announcements of major research projects, breakthroughs in genetic diagnostics, or changes in government funding for science can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Illumina shares, like those of the entire genetic research sector, are driven by general news about scientific breakthroughs and research funding. Advances in genomics and personalized medicine are a common trend. The chart will show whether the company maintains its technological leadership.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Illumina is a leader in DNA sequencing. The company's technologies are at the heart of the genomic revolution. However, its business has seen a slowdown. The chart shows how the company's shares, once a growth story, are now more sensitive to overall market sentiment.
Market capitalization of the company, segment and market as a whole
ILMN - Market capitalization of the company Illumina Inc.
Illumina's market capitalization is a financial valuation of the company's dominant position in genome sequencing. The chart reflects how investors view the future of genetic research and personalized medicine. Its dynamics tell the story of the technological leadership that has made DNA sequencing accessible to scientists and clinics worldwide.
ILMN - Share of the company's market capitalization Illumina Inc. within the market segment - Medanalysis
Illumina, Inc. is a global leader in DNA sequencing and genome analysis. The company's market capitalization is nearly monopolistic, reflecting its technological dominance in genetic research. The chart shows the weight of this undisputed leader.
Market capitalization of the market segment - Medanalysis
Illumina is the undisputed leader in gene sequencing. The chart below shows the overall market capitalization of the healthcare analytics sector. Its dynamics reflect the revolution in personalized medicine. In this field, Illumina provides the very tools that allow us to read the "book of life" and fight disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Genomics is a cutting-edge field of science, generating enormous future value, which is only partially visible on the chart. Illumina is a leader in DNA sequencing technology. Its market cap reflects a bet that genome sequencing will become the foundation for personalized medicine and biotechnology.
Book value capitalization of the company, segment and market as a whole
ILMN - Book value capitalization of the company Illumina Inc.
For Illumina, a leader in genome sequencing, this chart is the material foundation of the genetic revolution. The growth in book value reflects investments in factories producing sophisticated sequencing equipment and reagents. These are the physical assets that enable scientists and doctors to read the book of life.
ILMN - Share of the company's book capitalization Illumina Inc. within the market segment - Medanalysis
Illumina's share of the life sciences sector is determined by its high-tech manufacturing facilities. The company controls DNA sequencer and reagent production facilities, creating the physical foundation for a global revolution in genomics and personalized medicine.
Market segment balance sheet capitalization - Medanalysis
Illumina is a leader in DNA sequencing. The production of their complex instruments and reagents requires high-tech, sterile manufacturing facilities. The book value chart reflects the value of this scientific and manufacturing base, which underpins their dominance in the genomics market.
Book value of all companies included in the broad market index - GURU.Markets
Illumina's core assets are high-tech factories and laboratories where they create DNA sequencing equipment that advances medicine and science. The chart below shows how the company has grown its manufacturing and research capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Illumina Inc.
Illumina owns DNA sequencing facilities. But the market doesn't value them; it values their near-monopoly position in genomics and the future of personalized medicine. The chart shows how much their faith in this revolution exceeded the value of their assets.
Market to book capitalization ratio in a market segment - Medanalysis
Illumina is a leader in gene sequencing. Its value is determined by its technological dominance and patents. The chart shows how much its market valuation, based on expected growth in the genetics market, exceeds the value of its tangible assets. Compare this premium with other life sciences companies.
Market to book capitalization ratio for the market as a whole
Illumina is a global leader in DNA sequencing, its equipment at the core of genomic research. If this chart represents an average, then Illumina is a company whose value lies in its technology and dominant position. The market values it as the creator of an entire ecosystem, where it sells not only equipment but also high-end consumables, creating a significant premium to its balance sheet.
Debts of the company, segment and market as a whole
ILMN - Company debts Illumina Inc.
Illumina, the undisputed leader in the gene sequencing market, uses its capital to fund groundbreaking research and maintain its technological dominance. This chart shows how the company is investing in developing new, faster, and cheaper DNA analysis platforms, necessitating massive R&D expenditures to stay ahead of the competition.
Market segment debts - Medanalysis
Illumina, a leader in DNA sequencing technology, provides tools that have revolutionized genetics and medicine. To maintain its technological edge, the company invests heavily in R&D. This chart shows the level of financial leverage the company considers acceptable to maintain its dominance.
Market debt in general
Illumina, Inc., a leader in DNA sequencing, spends heavily on R&D to remain at the forefront of genomic science. This chart, showing its cost of capital, is important for assessing its investment strategy. Illumina's debt load has increased following a controversial acquisition, and the company now faces the challenge of proving the feasibility of the deal to the market through future revenue generation.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Illumina Inc.
Illumina is a leader in the DNA sequencing market, its technologies underpinning genomic research. This chart shows its debt burden, which may have increased due to ambitious but controversial acquisitions. The company needs to generate stable demand for its expensive instruments and consumables to service its debt, otherwise it will hinder its growth.
Market segment debt to market segment book capitalization - Medanalysis
Illumina is a global leader in DNA sequencing technology, its equipment setting the standard for genetic research. It's a knowledge-intensive business, requiring colossal investments in R&D. This chart shows how the biotech sector as a whole uses debt to fund breakthrough innovations, and how Illumina compares.
Debt to book value of all companies in the market
Illumina is the dominant player in the DNA sequencing market. It's a knowledge-intensive business, requiring colossal investments in R&D. This chart shows the average debt load of the entire economy. It allows us to assess how Illumina's financial model, based on technological leadership, differs from traditional industries.
P/E of the company, segment and market as a whole
P/E - Illumina Inc.
Illumina is the undisputed leader in genome sequencing technology, its equipment used in scientific research, medicine, and genetic testing. This chart reflects the investors' high expectations for a revolution in personalized medicine. High values indicate the belief that DNA sequencing will become routine, opening up new markets.
P/E of the market segment - Medanalysis
Illumina is the undisputed leader in DNA sequencing. The company's technology has revolutionized genetics, medicine, and biotechnology, making genome sequencing fast and accessible. This chart shows the average valuation for the medical analysis sector, demonstrating how highly investors value companies unlocking the mysteries of life.
P/E of the market as a whole
Illumina is a global leader in DNA sequencing, providing equipment and reagents for genetic analysis. This chart reflects the overall sentiment in the biotech sector, but for ILMN, advances in genomics are key. The company's valuation is a bet on the future of personalized medicine and scientific discovery.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Illumina Inc.
Illumina is the undisputed leader in the DNA sequencing market, providing instruments and reagents for genetic analysis. This chart reflects investors' faith in the future of genomics and personalized medicine. Its momentum is a long-term bet that genome sequencing will become standard practice in medicine and scientific research, fueling Illumina's growth.
%20P%2FE%20Illumina%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Illumina-Inc.&v=1772653925365 "Chart of the company's future (projected) P/E Illumina Inc.")
Future (projected) P/E of the market segment - Medanalysis
Illumina is a global leader in DNA sequencing, providing the technologies that underpin genomic research. This chart shows the company's estimated future revenue in the context of the biotech sector. It illustrates how investors view its market dominance and growth prospects in an increasingly competitive environment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772653925373 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Illumina is the undisputed leader in DNA sequencing technology, whose equipment is used in scientific research and genetic diagnostics. Despite the general market fluctuations shown by this chart, Illumina's business depends on long-term trends in science and medicine. R&D budgets and the implementation of genomics in healthcare are its main drivers.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653925397 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Illumina Inc.
Illumina is the undisputed leader in the DNA sequencing market. The company produces equipment and reagents used in genetic research worldwide. This chart shows the financial performance of this business, which is the "gold standard" in genetics and the foundation for the development of personalized medicine.
Profit of companies in the market segment - Medanalysis
Illumina is a leader in DNA sequencing, whose technologies underpin genomic research. This chart reflects profitability in the life sciences sector. For Illumina, it reflects its investment in scientific research and personalized medicine. This growth signifies the world's increasing use of genetic data for scientific breakthroughs.
Overall market profit
Illumina is the undisputed leader in DNA sequencing. The company's technologies underpin genomic research, genetic diagnostics, and personalized medicine. This is a rapidly growing market driven by scientific advancement. Illumina's financial performance is less dependent on the general economic cycle (shown in the chart) and more dependent on research and healthcare budgets.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Illumina Inc.
Illumina is the undisputed leader in the DNA sequencing market. The company's profit forecast, shown in this chart, reflects expectations for the growing application of genomic technologies in medicine and scientific research. The pace of clinical adoption of genetic testing is a key factor assessed by Wall Street analysts.
%20profit%20of%20the%20company%20Illumina%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Illumina-Inc.&v=1772653925616 "Graph of future (projected) profit of the company Illumina Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Illumina is the undisputed leader in the genome sequencing market, whose technologies underpin genetic research worldwide. The revenue forecast for this segment depends on research funding and the adoption of genetic testing in clinical practice. This chart shows the collective analyst outlook on the future of the genomics market, which promises to revolutionize medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772653925617 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Illumina is a leader in DNA sequencing and genomic analysis. The company's growth depends on investments in scientific research and personalized medicine. The revenue projections reflected here impact public and private R&D funding, which is vital to the continued deployment of Illumina's technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653925653 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Illumina Inc.
Illumina is the absolute dominant player in the gene sequencing market. This chart shows its historically high revenue valuation, reflecting investors' faith in a revolution in personalized medicine. The market is willing to pay a premium for its sales, seeing them as the key to the future of healthcare, even if growth slows temporarily.
P/S market segment - Medanalysis
Illumina is the undisputed leader in DNA sequencing, providing the instruments and reagents that underpin genomic research worldwide. This chart shows the average market capitalization-to-revenue ratio for the biotech industry. It illustrates the premium investors are willing to pay for Illumina's dominant position and its key role in the future of medicine.
P/S of the market as a whole
Illumina is the undisputed leader in the gene sequencing market, providing equipment and consumables for genetic research. The company's growth is fueled by the revolution in personalized medicine and biotechnology. This chart provides a market-wide backdrop for assessing investor sentiment on the long-term revenue prospects of this innovative and knowledge-intensive industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Illumina Inc.
Illumina is a global leader in DNA sequencing, providing technologies for genetic research and diagnostics. This chart reflects how the market values the company's future revenue. It demonstrates investor confidence in the genetics-driven revolution in personalized medicine and biotechnology.
%20P%2FS%20Illumina%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Illumina-Inc.&v=1772653925825 "The graph of the company's future (projected) P/S Illumina Inc.")
Future (projected) P/S of the market segment - Medanalysis
Illumina is the undisputed leader in gene sequencing technology, providing tools for genetic research and diagnostics. Its growth is driven by advances in personalized medicine and scientific discoveries. This chart illustrates the market's appreciation for its technological dominance and potential to revolutionize healthcare.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772653925841 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Illumina is a global leader in DNA sequencing, providing equipment and reagents for genetic research. Demand for its products depends on scientific and medical budgets. This market optimism curve is important because it impacts the availability of funding for research institutes and biotech startups, which are Illumina's key clients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653925879 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Illumina Inc.
Illumina is the undisputed leader in DNA sequencing technology, producing instruments and reagents that enable the reading of genetic code. This graph illustrates progress in genetics and personalized medicine. Revenue growth is directly driven by demand from research laboratories, pharmaceutical companies, and clinics using genomic analysis for research and diagnostics.
Sales of companies in the market segment - Medanalysis
Illumina is the undisputed leader and pioneer in DNA sequencing. Their equipment and technology have made genome sequencing possible quickly and affordably, revolutionizing medicine and biology. Their revenue structure clearly shows that their primary revenue stream comes not so much from the equipment itself as from the consumables used to perform the tests.
Overall market sales
Illumina is a global leader in DNA sequencing. The company's technologies have revolutionized genetics, medicine, and biotechnology, making genome analysis accessible. Demand for its equipment and reagents reflects the pace of scientific research. This graph of overall economic activity includes the innovative healthcare sector, where Illumina is a technological foundation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Illumina Inc.
Illumina is a global leader in DNA sequencing technology, providing instruments and reagents for genetic research. This chart reflects analyst revenue forecasts, which are driven by genomics market growth, investment in research, and the adoption of genetic testing in clinical practice for disease diagnosis.
%20sales%20of%20the%20company%20Illumina%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Illumina-Inc.&v=1772653926051 "Schedule of future (projected) sales of the company Illumina Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Illumina is a global leader in DNA sequencing technology, producing equipment that "reads" the genetic code. This chart shows the growth forecast for the entire genetic analysis and genomics market. It illustrates how quickly analysts expect genetic technologies to penetrate medicine, science, and agriculture.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772653926094 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Illumina is a global leader in DNA sequencing, providing tools for genetic research. This chart, which reflects overall economic forecasts, is important to the company because it influences public and private science budgets. Economic growth ensures stable funding for research institutes and biotech companies—Illumina's key clients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653926106 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Illumina Inc.
Illumina, a leader in DNA sequencing, demonstrates its profitability in this chart. The company's profitability is based on a "razor and blades" business model: it sells genetic analysis equipment (sequencers) and then generates stable revenue from the consumables and reagents needed to operate them. This ensures high and predictable margins.
Market segment marginality - Medanalysis
Illumina, Inc. is a global leader in DNA sequencing and genomic analysis, whose technologies underpin many medical breakthroughs. The company's profitability is determined by its technological dominance and the cost of consumables. This chart reflects the profitability of their unique business model. Their dominance over the industry indicates a near-monopoly position in the genomics market.
Market marginality as a whole
Illumina is the undisputed leader in the DNA sequencing market. The company's technologies are the foundation for genetic research and personalized medicine. Illumina's growth is driven by the speed of scientific discovery and the falling cost of genomic analysis, rather than by the general economic cycles reflected in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company Illumina Inc.
Illumina is the undisputed leader in gene sequencing technology. Its equipment made possible the decoding of the human genome and revolutionized medicine. This graphic shows the team of highly skilled scientists, engineers, and bioinformaticians who create the tools that underpin personalized medicine and genetic research worldwide.
Share of the company's employees Illumina Inc. within the market segment - Medanalysis
Illumina is the undisputed leader in DNA sequencing technology, whose instruments are used in genomic research worldwide. This chart demonstrates its scientific dominance. It reflects the overwhelming share of geneticists, bioinformaticians, and engineers in the genomics industry that Illumina attracts, enabling breakthroughs in medicine and biotechnology.
Number of employees in the market segment - Medanalysis
Illumina is a global leader in DNA sequencing, and its technology has revolutionized genetics and medicine. This business is at the forefront of science. This chart shows the growing number of scientists and technicians creating tools for reading genomes, paving the way for personalized medicine and new methods of disease diagnosis.
Number of employees in the market as a whole
Illumina is a global leader in DNA sequencing and genomic analysis. The company's technologies advance scientific research and personalized medicine. Economic health, reflected by overall employment growth in this graph, directly impacts science and healthcare funding. Steady growth enables increased investment in genetic research, expanding Illumina's market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Illumina Inc. (ILMN)
Illumina is a global leader in DNA sequencing. This chart demonstrates a business built on technological dominance. Its very high market capitalization per employee reflects the fact that the company's market value is determined by its patents, sophisticated equipment, and software developed by an elite team of scientists and engineers.
%20of%20the%20company%20Illumina%20Inc.%20(ILMN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Illumina-Inc.-ILMN&v=1772653926455 "Chart of market capitalization per employee (in thousands of dollars) of the company Illumina Inc. (ILMN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Illumina is a near-monopoly in DNA sequencing technology. The company's value lies not in its people, but in its unique, patented technology, which is the gold standard in science. This chart shows the industry average, clearly demonstrating the enormous market value generated by each employee of the company that owns its core technology.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772653926563 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Illumina is a leader in DNA sequencing and genome analysis. This figure is one of the highest in the biotechnology equipment industry. It reflects the company's near-monopoly position and the enormous value of its technologies, which underpin modern genetics and personalized medicine. This value is created by scientists and patents.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653926617 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Illumina Inc. (ILMN)
Illumina is a virtual monopoly in the DNA sequencing equipment market. This chart reflects their unique "razor and blades" business model. The company sells expensive machines (sequencers) and then generates stable, high-margin revenue from the sale of consumables (reagents) for them. This model ensures the highest profitability per R&D and manufacturing staff.
%20Chart%20Illumina%20Inc.%20(ILMN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Illumina-Inc.-ILMN&v=1772653926652 "Company Profit Per Employee (in thousands of dollars) Chart Illumina Inc. (ILMN)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Illumina is the dominant leader in DNA sequencing (reading) machines. This graph shows the benchmark for "Medanalysis." In this sector (Life Science Tools), the benchmark is *off the charts*. It's a "monopoly" razor-and-blade model: profit is generated by the "consumables" (reagents) required to operate their DNA "printers."
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772653926662 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Illumina is a global leader in DNA sequencing and genome analysis. This chart, demonstrating the value of human capital, clearly illustrates the specifics of their business. The company creates tools that advance the field of genetics. A small team of scientists and engineers produces equipment that generates enormous revenue and profits for the company.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653926695 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Illumina Inc. (ILMN)
Illumina is a global leader in DNA sequencing and genome analysis. This chart reflects its market dominance and the value of its technologies. Its colossal revenue per employee is the result of selling expensive equipment and consumables for genetic research, where intellectual property generates the bulk of its cash flow.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Illumina-Inc.-ILMN&v=1772653926814 "Sales chart per company employee Illumina Inc. (ILMN)")
Sales per employee in the market segment - Medanalysis
Illumina is the dominant player in gene sequencing. They produce machines (sequencers) and reagents for DNA analysis. Their business model is a "razor and blades" approach: expensive equipment and constant sales of consumables. This chart demonstrates how effective this knowledge-intensive model is. It compares how their team (scientists and engineers) generates revenue compared to other players in the medical device sector.
Sales per employee for the market as a whole
Illumina is a near-monopoly in the gene sequencing industry. They produce machines that "read" DNA. Their business follows the classic "razor and blades" model: they sell expensive machines, but their primary revenue comes from renewable consumables (reagents). This chart shows how much revenue their R&D generates.
Short shares by company, segment and market as a whole
Shares shorted by company Illumina Inc. (ILMN)
Illumina (ILMN) is the dominant player in the DNA sequencing market. Their equipment is the standard for scientific and medical laboratories. This chart measures bearish sentiment. The high short interest in ILMN is due to market disappointment with growth rates, regulatory concerns (antitrust cases), and increasing competition in the genetic analysis industry.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Illumina-Inc.-ILMN&v=1772653926952 "Short Shares Chart for the Company Illumina Inc. (ILMN)")
Shares shorted by market segment - Medanalysis
Illumina (ILMN) is a dominant player in the DNA sequencing market, supplying instruments and reagents for genetic research. This chart demonstrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about declining R&D funding or increased competition across the genomics industry.
Shares shorted by the overall market
Illumina (ILMN) is a virtual monopoly in DNA sequencing equipment. It's the "spade" for the genomic revolution. This chart shows the overall level of fear. When pessimism rises, investors fear for ILMN. Their clients (biotech companies and labs) may cut R&D budgets and postpone purchasing expensive sequencers until better times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Illumina Inc. (ILMN)
Illumina is a leader in DNA sequencing. Its business depends on R&D budgets in biotech and academia. This chart, above 70, may reflect strong demand for its equipment. A level below 30 is often associated with concerns about R&D budget cuts (a "venture winter") or problems following M&A.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Illumina-Inc.-ILMN&v=1772653927238 "RSI 14 indicator chart for the company's stock Illumina Inc. (ILMN)")
RSI 14 Market Segment - Medanalysis
Illumina (ILMN) is the dominant player in the gene sequencing market. Their machines are the "gold standard" for genetic research in science and medicine. They read the "book of life." This chart measures the pulse of the Medical Analysis sector. It helps investors understand whether ILMN's momentum is driven by their technology or whether the entire industry is overheated by genomics hype or oversold due to regulatory concerns.
RSI 14 for the overall market
Illumina (ILMN) is the dominant player in the gene sequencing market. Their machines are the "gold standard" for genetic research. This chart measures overall market euphoria. ILMN is a growth stock. During periods of overheating, its valuation can be overstated. During panic, investors may fear R&D budget cuts at Illumina's clients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ILMN (Illumina Inc.)
Illumina (ILMN) is the dominant manufacturer of DNA sequencing equipment. It is the technological foundation of the genomic revolution. The company is going through a challenging period. This chart shows the average analyst forecast, reflecting concerns about slowing demand from biotech and the fallout from the controversial Grail acquisition.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ILMN-Illumina-Inc.&v=1772653927394 "A chart showing analyst consensus forecasts for the expected stock price. ILMN (Illumina Inc.)")
The difference between the consensus estimate and the actual stock price ILMN (Illumina Inc.)
Illumina is the absolute dominant player in the DNA sequencing market. Their equipment and reagents are the standard for genetic research in science and medicine. This chart shows the difference between the market's current valuation of the company and the analyst consensus target. This reflects their expectations for growth in the genomics and clinical diagnostics market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ILMN-Illumina-Inc.&v=1772653927487 "A chart showing the difference between the consensus forecast and the actual stock price. ILMN (Illumina Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Illumina has a virtual monopoly on the gene sequencing market. Its machines and consumables are the "gold standard" for genetic research in science and medicine. This chart shows analysts' general expectations for the medical analysis sector. It reflects whether experts believe in a genomics boom or anticipate a decline in R&D.
Analysts' consensus forecast for the overall market share price
Illumina is the dominant player in the DNA sequencing market. They sell printers (sequencers) and cartridges for them. Their customers are research centers and biotech companies. Market expectations, as shown in this graph, influence R&D budgets. If investors are pessimistic, biotech companies have a harder time raising funds for research and purchase fewer Illumina cartridges.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Illumina Inc.
Illumina is essentially a monopoly in DNA sequencing. Their machines are the gold standard for genetic research in science and medicine. This graph reflects their razor-and-blades business model (instruments and consumables). It measures the pace of scientific research, but also the consequences of their failed attempt to acquire Grail (cancer testing).
AKIMA Market Segment Index - Medanalysis
Illumina is a monopoly in genetics; the company produces machines (sequencers) and consumables that are the gold standard for DNA sequencing (research, medicine). This aggregate metric evaluates companies. The graph shows the sector average. This benchmark: how does Illumina's razor-sharp monopoly in sequencing differentiate it from the average competitor?
The AKIM Index for the overall market
Illumina is the dominant (almost monopolistic) genomic sequencing market leader. Its machines are the gold standard for biotech and science, enabling DNA reading. This chart, reflecting the market average, is a backdrop. It helps assess how Illumina, whose business relies on R&D budgets in the defense sector, stacks up against the overall macroeconomic picture, which influences risk appetite.
